炎症性肠病(IBD)是一种影响胃肠道的慢性炎症性疾病,通常会导致腹痛和腹泻等症状。鉴于越来越多的证据将全身性炎症与心房颤动的发展联系起来,将IBD作为房颤的潜在危险因素进行调查势在必行.本荟萃分析旨在评估心房颤动对住院患者预后的影响,资源利用率,和IBD患者的住院时间。遵循系统评价和荟萃分析(PRISMA)2020指南的首选报告项目,在多个数据库中进行了系统的文献检索,包括Embase,PubMed,Scopus,和WebofScience,从数据库开始到2024年6月5日。符合条件的研究包括明确诊断为溃疡性结肠炎的前瞻性或回顾性研究。克罗恩病,或IBD,证明心房颤动的影响。数据被提取,使用纽卡斯尔-渥太华量表进行质量评估。荟萃分析包括842,149例IBD患者,有71,221例房颤.汇总分析显示,房颤与全因死亡风险升高之间存在显著关联(风险比(RR):1.42,95%置信区间(CI):1.16~1.74,p<0.01)。然而,在急性心肌梗死的发生率方面没有观察到显著差异,急性肾损伤,或有和没有房颤的患者之间的急性呼吸衰竭。合并房颤的IBD患者面临更高的死亡率,可能是由于全身性炎症,血栓栓塞风险,多药,以及同时管理这两种条件的复杂性。IBD患者房颤的早期识别和综合管理对于改善预后至关重要。较大,需要多中心研究来探索潜在的机制并制定量身定制的治疗策略.
Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract, often leading to symptoms like abdominal pain and diarrhea. Given the increasing evidence linking systemic inflammation to atrial fibrillation development, investigating IBD as a potential risk factor for atrial fibrillation becomes imperative. This meta-analysis aims to evaluate the impact of atrial fibrillation on inpatient outcomes, resource utilization, and length of hospital stays among IBD patients. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines, a systematic literature search was conducted across multiple databases, including Embase, PubMed, Scopus, and Web of Science, from the inception of databases to June 5, 2024. Eligible studies included prospective or retrospective studies with definitive diagnoses of ulcerative colitis, Crohn\'s disease, or IBD, demonstrating the influence of atrial fibrillation. Data were extracted, and quality assessment was performed using the Newcastle-Ottawa Scale. The meta-analysis comprised 842,149 IBD patients, with 71,221 having atrial fibrillation. Pooled analysis revealed a significant association between atrial fibrillation and heightened all-cause mortality risk (risk ratio (RR): 1.42, 95% confidence interval (CI): 1.16 to 1.74, p<0.01). However, no significant differences were observed in the incidence of acute myocardial infarction, acute kidney injury, or acute respiratory failure between patients with and without atrial fibrillation. IBD patients with comorbid atrial fibrillation face higher mortality rates, potentially due to systemic inflammation, thromboembolism risks, polypharmacy, and the complexities of managing both conditions concurrently. Early identification and integrated management of atrial fibrillation in IBD patients are crucial to improving outcomes. Larger, multi-center studies are needed to explore the underlying mechanisms and develop tailored treatment strategies.